SG Americas Securities LLC Buys New Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

SG Americas Securities LLC purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 146,491 shares of the company’s stock, valued at approximately $239,000. SG Americas Securities LLC owned 0.07% of Sana Biotechnology as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SANA. Barclays PLC increased its holdings in shares of Sana Biotechnology by 126.6% in the 3rd quarter. Barclays PLC now owns 318,910 shares of the company’s stock valued at $1,325,000 after acquiring an additional 178,179 shares during the period. FMR LLC grew its position in Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the last quarter. Geode Capital Management LLC increased its stake in Sana Biotechnology by 9.6% in the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock valued at $13,175,000 after purchasing an additional 276,055 shares during the period. Stifel Financial Corp purchased a new stake in shares of Sana Biotechnology in the third quarter valued at about $43,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Sana Biotechnology by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock worth $4,359,000 after buying an additional 105,382 shares during the period. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SANA. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright lifted their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.25.

Insider Activity at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 31.10% of the stock is currently owned by company insiders.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $3.26 on Friday. The stock has a market capitalization of $727.86 million, a price-to-earnings ratio of -2.33 and a beta of 1.59. Sana Biotechnology, Inc. has a 1 year low of $1.52 and a 1 year high of $12.00. The stock has a fifty day moving average price of $2.63 and a two-hundred day moving average price of $3.76.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. On average, analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.